iBio, Inc. filed a Form 8-K to update its corporate presentation for investor and analyst meetings. The updated materials highlight the company's pipeline of next-generation antibody therapies targeting obesity and cardiometabolic diseases, specifically IBIO-610 (Activin E), IBIO-800 (Myostatin x Activin A bispecific), and IBIO-600 (Myostatin). Key anticipated milestones include an IND equivalent filing for IBIO-610 in 2H 2026, Phase 1 initiation for IBIO-610 in 1H 2027, and interim Phase 1 data for IBIO-600 in 1Q 2027. The company reported $88.0 million in cash as of June 30, 2026, with a runway extending into Q4 FY 2028. iBio, Inc. operates in the biotechnology industry, developing antibody-based therapeutics for metabolic and cardiovascular conditions.
